Irlbeck M, Zimmer H G
Department of Physiology, University of Munich, Munchen, Germany.
Cardiovasc Res. 1993 Dec;27(12):2146-51. doi: 10.1093/cvr/27.12.2146.
Although the haemodynamic effects of catecholamines on the rat left ventricle have been investigated extensively, only few systematic in vivo studies have been performed on the right ventricle. The aim was to examine the acute effects of noradrenaline and isoproterenol on rat right ventricular function.
Haemodynamic variables were measured during acute, 20 minute infusion of noradrenaline (0.1 mg.kg-1 x h-1) or isoproterenol (12 micrograms.kg-1 x h-1) in female Sprague Dawley rats. To estimate the contribution of alpha and beta receptor stimulation to these effects, eight rats each were infused with prazosin (0.1 mg.kg-1 x h-1), metoprolol (1.0 mg.kg-1 x h-1), or the alpha and beta antagonist carvedilol (0.5 and 1.0 mg.kg-1 x h-1) alone and in combination with noradrenaline or isoproterenol.
Noradrenaline and isoproterenol increased right ventricular systolic pressure (RVSP) from 30.3 (SEM 0.5) (n = 32) to 72.7(2.7) (n = 24) and 72.3(4.4) (n = 8) mm Hg, right ventricular (RV) dP/dtmax from 1848(70.3) to 4058(301) and 3612(366) mm Hg.s-1, and heart rate from 329(6) to 371(6) and 420(8) beats.min-1, respectively. Metoprolol completely prevented the isoproterenol induced haemodynamic changes, but neither metoprolol nor prazosin was able to significantly affect the pressure effect of noradrenaline (noradrenaline + metoprolol: 67.3(6.9) mm Hg, noradrenaline + prazosin: 67.0(3.8) mm Hg). The combination of both blockers, however, prevented the noradrenaline induced rise in RVSP (noradrenaline + metoprolol + prazosin: 36.5(5.1), and noradrenaline + prazosin + metoprolol: 30.0(1.2) mm Hg). Carvedilol (1.0 mg.kg-1 x h-1) significantly attenuated the noradrenaline induced RVSP increase (39.1(3.0) mm Hg), but not to the control range. Metoprolol or carvedilol completely prevented the noradrenaline elicited increases in heart rate (254(7) and 287(20) min-1) and RVdP/dtmax, but prazosin alone had no effect on the heart rate and RVdP/dtmax increase. Thus beta receptor blockade alone failed to significantly influence the noradrenaline induced increase of RVSP despite prevention of the increase in heart rate and RVdP/dtmax. Prazosin had a significant effect on RVSP only in combination with metoprolol.
The combined effect of both alpha and beta blockade exceeds the pure addition of the single effects in the rat right ventricle. Moreover, we speculate that the failure to reduce the noradrenaline induced increase in RVSP by either alpha or beta blockade alone is due to the stimulation of the receptor that is not affected by the respective blocker.
尽管已对儿茶酚胺对大鼠左心室的血流动力学效应进行了广泛研究,但对右心室进行的系统性体内研究却很少。本研究旨在探讨去甲肾上腺素和异丙肾上腺素对大鼠右心室功能的急性影响。
对雌性斯普拉格-道利大鼠进行急性20分钟输注去甲肾上腺素(0.1mg·kg⁻¹·h⁻¹)或异丙肾上腺素(12μg·kg⁻¹·h⁻¹),期间测量血流动力学变量。为评估α和β受体刺激对这些效应的贡献,每组8只大鼠分别单独输注哌唑嗪(0.1mg·kg⁻¹·h⁻¹)、美托洛尔(1.0mg·kg⁻¹·h⁻¹)或α和β受体拮抗剂卡维地洛(0.5和1.0mg·kg⁻¹·h⁻¹),并与去甲肾上腺素或异丙肾上腺素联合输注。
去甲肾上腺素和异丙肾上腺素分别使右心室收缩压(RVSP)从30.3(标准误0.5)(n = 32)升高至72.7(2.7)(n = 24)和72.3(4.4)(n = 8)mmHg,右心室(RV)dP/dtmax从1848(70.3)升高至4058(301)和3612(366)mmHg·s⁻¹,心率从329(6)升高至371(6)和420(8)次/分钟。美托洛尔完全阻止了异丙肾上腺素诱导的血流动力学变化,但美托洛尔和哌唑嗪均不能显著影响去甲肾上腺素的压力效应(去甲肾上腺素 + 美托洛尔:67.3(6.9)mmHg,去甲肾上腺素 + 哌唑嗪:67.0(3.8)mmHg)。然而,两种阻滞剂联合应用可阻止去甲肾上腺素诱导的RVSP升高(去甲肾上腺素 + 美托洛尔 + 哌唑嗪:36.5(5.1),去甲肾上腺素 + 哌唑嗪 + 美托洛尔:30.0(1.2)mmHg)。卡维地洛(1.0mg·kg⁻¹·h⁻¹)显著减弱了去甲肾上腺素诱导的RVSP升高(39.1(3.0)mmHg),但未降至对照范围。美托洛尔或卡维地洛完全阻止了去甲肾上腺素引起的心率升高(254(7)和287(20)次/分钟)以及RVdP/dtmax升高,但单独使用哌唑嗪对心率和RVdP/dtmax升高无影响。因此,尽管阻止了心率和RVdP/dtmax升高,但单独的β受体阻滞未能显著影响去甲肾上腺素诱导的RVSP升高。哌唑嗪仅与美托洛尔联合应用时对RVSP有显著影响。
α和β受体阻滞的联合效应超过了大鼠右心室中单一效应的简单相加。此外,我们推测单独使用α或β受体阻滞未能降低去甲肾上腺素诱导的RVSP升高是由于未受相应阻滞剂影响的受体受到了刺激。